Oltmans Curtis Gale

Track

Insider profile

Performance

Overall performance
2.5
Performance over holding periods
2.5
30 days 90 days 120 days
Average return -15% 8.2% 15.1%
Success rate 0% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Oltmans Curtis Gale's trades of Fulcrum Therapeutics, Inc.'s stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
454.87
Quantity 87,098 +33.9%
Value US$2,583,592
Transaction date
Planned sale
Price
20.00
Quantity 40,000 -72.7%
Value US$800,000
Transaction date
Planned sale
Price
18.00
Quantity 14,029 -78.2%
Value US$252,523
Transaction date
Planned sale
Price
18.00
Quantity 1,251 -24.2%
Value US$22,518
Transaction date
Planned sale
Price
18.06
Quantity 19,720 -83.4%
Value US$356,139
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-17 2025-12-15
PlS Planned sale
2,984 +3.1%
401.09
US$4,600,048 		2,984 +3.1% 401.09 US$4,600,048
2025-12-15 2025-12-15
PrS Proposed sale
44,272
30.79
US$1,175,062 		44,272 30.79 US$1,175,062
2021-06-29 2021-06-28
B Purchase
87,098 +33.9%
454.87
US$2,583,592 		87,098 +33.9% 454.87 US$2,583,592
2019-02-07 2019-02-05
PlS Planned sale
40,000 -72.7%
20.00
US$800,000 		40,000 -72.7% 20.00 US$800,000
2019-01-29 2019-01-25
PlS Planned sale
14,029 -78.2%
18.00
US$252,523 		14,029 -78.2% 18.00 US$252,523
2019-01-23 2019-01-18
PlS Planned sale
1,251 -24.2%
18.00
US$22,518 		1,251 -24.2% 18.00 US$22,518
2019-01-17 2019-01-15
PlS Planned sale
19,720 -83.4%
18.06
US$356,139 		19,720 -83.4% 18.06 US$356,139